Opening stock page...
Fetching company snapshot, pricing, and intelligence.
Intelligence coverage: 60%
Basic profile, financials, and market data are shown below. Deep research is building in the background.
AI confidence 50% · prior close shown (market closed)
Limited proprietary earnings coverage for LIMN yet — signals will sharpen as filings and earnings are ingested.
Pipeline evidence · 15d ago
LIMN's AlphaOS Signals
Upgrade to Pro for validated historical pattern analysis on LIMN.
Free accounts see more of this; Premium sees all of it.
Updated
What happened recently for Liminatus Pharma, Inc. (LIMN) — events, not interpretation.
Research & analysis only — not investment advice.
AlphaOS industries
Investment snapshot
LIMN's AI investment thesis
Upgrade to Premium for LIMN's full multi-agent investment thesis.
Free accounts see more of this; Premium sees all of it.
Unified data coverage and cross-signal highlights — market, SEC, earnings, opportunity
Strengthen intelligence
Prior close
$4.20
Market cap
$281.74M
Profitable
—
Net income
—
FY Jul 26, 2026
Loading Wall Street consensus…
Loading earnings intelligence…
Building technical intelligence snapshot — check back shortly.
Loading market context…
No price history. Sync market data to load charts.
Loading SEC filing intelligence…
No filings ingested yet.
Investment Snapshot above is the primary AlphaOS analysis for Liminatus Pharma, Inc. — structured signals and evidence from proprietary pipelines, not an encyclopedia overview.
Research & analysis only — not investment advice. Price, charts, and filings are above.
Follow Liminatus Pharma, Inc. through AlphaOS's knowledge graph — themes, peers, beneficiaries, earnings, and research answers.
Connected companies and research pages from the AlphaOS knowledge graph.